← Search & browse all drugs

pethidine, combinations excl. psycholeptics

N02AB52

Forms & Strengths

Oral tablet formulations containing pethidine hydrochloride combined with non-opioid analgesics or antispasmodics (varies by regional availability)
Parenteral combination solutions for injection (historically available in select markets)

Adult Dosing

Acute moderate to severe pain: Oral/Parenteral doses equivalent to 50-150 mg pethidine hydrochloride every 3-4 hours as needed
Max daily dose: Typically not to exceed 600 mg/24 hours due to risk of toxic metabolite accumulation (normeperidine)

Pediatric Dosing

Safety and efficacy in pediatric patients not well established for combination products
Generally avoided in children due to high risk of central nervous system toxicity and respiratory depression

Indications

Short-term management of acute moderate to severe pain where combination therapy is deemed appropriate
Relief of acute visceral spasm or biliary colic (in specific regional formulations)

Mechanism of Action

Pethidine acts primarily as a mu-opioid receptor agonist providing central analgesia
May possess local anesthetic properties and anticholinergic-like effects depending on the specific combination agent

Contraindications

Hypersensitivity to pethidine or any components of the combination product
Concomitant MAO inhibitor use or within 14 days of cessation (risk of severe serotonin syndrome)
Significant respiratory depression, acute or severe bronchial asthma, or hypercarbia
Known or suspected gastrointestinal obstruction, including paralytic ileus

Adverse Reactions

Central nervous system: Dizziness, sedation, confusion, dysphoria, seizures (due to normeperidine accumulation)
Respiratory: Respiratory depression
Cardiovascular: Hypotension, tachycardia, syncope
Gastrointestinal: Nausea, vomiting, constipation, dry mouth
Other: Urinary retention, diaphoresis, tolerance and dependence with chronic use

Drug Interactions

Monoamine Oxidase Inhibitors (MAOIs): Absolute contraindication due to risk of fatal hyperpyrexia, excitation, or coma
CNS depressants (alcohol, benzodiazepines, general anesthetics): Potentiation of central nervous system and respiratory depression
Serotonergic drugs (SSRIs, SNRIs, tricyclics): Increased risk of serotonin syndrome
CYP3A4 inducers/inhibitors: May alter the metabolism of pethidine and its active metabolite

Curated Content: Needs Vetting Before Put to Clinical Use